These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31346365)

  • 1. Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis.
    Guptill JT; Runken MC; Eaddy M; Lunacsek O; Fuldeore RM
    Am Health Drug Benefits; 2019 May; 12(3):127-135. PubMed ID: 31346365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis.
    Anderson-Smits C; Ritchey ME; Huang Z; Chavan S; Souayah N; Ay H; Layton JB
    Neurol Ther; 2023 Aug; 12(4):1119-1132. PubMed ID: 37171778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Immunoglobulin Initiation in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims-based Cohort Study.
    Layton JB; Ritchey ME; Huang Z; Chavan S; Ay H; Souayah N; Anderson-Smits C
    Neurol Ther; 2023 Aug; 12(4):1171-1186. PubMed ID: 37195408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US.
    Guptill JT; Runken MC; Eaddy M; Lunacsek OE; Fuldeore RM; Blanchette CM; Zacherle E; Noone JM
    Patient Prefer Adherence; 2019; 13():649-655. PubMed ID: 31118588
    [No Abstract]   [Full Text] [Related]  

  • 6. Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression.
    Hung SKY; Hiew FL; Viswanathan S; Puvanarajah S
    J Peripher Nerv Syst; 2018 Sep; 23(3):183-189. PubMed ID: 30027593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.
    Bamrungsawad N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P; Dechanont S; Wu DB; Dejthevaporn C; Chaiyakunapruk N
    Clin Drug Investig; 2016 Jul; 36(7):557-66. PubMed ID: 27113227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
    Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
    Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice.
    Press R; Hiew FL; Rajabally YA
    Acta Neurol Scand; 2016 Apr; 133(4):228-38. PubMed ID: 26437234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States.
    Mallick R; Carlton R; Van Stiphout J
    Pharmacoecon Open; 2023 Mar; 7(2):243-255. PubMed ID: 36757567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance Intravenous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: 18-Month Post-marketing Surveillance in 103 Patients.
    Kuwabara S; Oh A; Arakawa M; Kikutani M; Okamatsu N; Sobue G
    Intern Med; 2024 Jul; ():. PubMed ID: 39019607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van Doorn PA; Bengrine T; van Rijs W; Baas F; Nagelkerke SQ; Kuijpers TW; Fokkink WR; Bunschoten C; Broers MC; Willemsen SP; Jacobs BC; Huizinga R
    Eur J Neurol; 2021 May; 28(5):1677-1683. PubMed ID: 33460483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
    Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.
    Blackhouse G; Gaebel K; Xie F; Campbell K; Assasi N; Tarride JE; O'Reilly D; Chalk C; Levine M; Goeree R
    Cost Eff Resour Alloc; 2010 Jun; 8():14. PubMed ID: 20565778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
    Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
    Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric-Onset Chronic Inflammatory Demyelinating Polyneuropathy: A Multicenter Study.
    Sarıkaya Uzan G; Vural A; Yüksel D; Aksoy E; Öztoprak Ü; Canpolat M; Öztürk S; Yıldırım Ç; Güleç A; Per H; Gümüş H; Okuyaz Ç; Çobanoğulları Direk M; Kömür M; Ünalp A; Yılmaz Ü; Bektaş Ö; Teber S; Aliyeva N; Olgaç Dündar N; Gençpınar P; Gürkaş E; Keskin Yılmaz S; Kanmaz S; Tekgül H; Aksoy A; Öz Tuncer G; Acar Arslan E; Tosun A; Ayanoğlu M; Kızılırmak AB; Yousefi M; Bodur M; Ünay B; Hız Kurul S; Yiş U
    Pediatr Neurol; 2023 Aug; 145():3-10. PubMed ID: 37245275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
    Guptill JT; Bromberg MB; Zhu L; Sharma BK; Thompson AR; Krueger A; Sanders DB
    Muscle Nerve; 2014 Jul; 50(1):47-51. PubMed ID: 24639235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
    Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
    J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.
    Runken MC; Noone JM; Blanchette CM; Zacherle E; Howden R
    Am Health Drug Benefits; 2019 Oct; 12(6):294-304. PubMed ID: 31908713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.